The primary therapeutic benefit of Тарег (Valsartan) plays a role in managing conditions associated with heightened systemic burden. The therapeutic applications are relevant for addressing several symptomatic domains. This medication is generally considered relevant for chronic conditions, primarily high blood pressure (hypertension), symptomatic chronic heart failure, and in patients following a myocardial infarction who have conditions where functional stability becomes affected.

Тарег is applied across domains where additional symptomatic support is needed. In managing elevated arterial pressure, it provides support that helps ease the overall symptom burden associated with systemic imbalance and helps improve day-to-day comfort during symptomatic periods. For heart failure, it helps address symptom clusters like fatigue and shortness of breath, and may help reduce the necessity for recurrent hospitalization. The treatment is also a relevant therapeutic option when patients require necessary cardiovascular support but demonstrate intolerance to Angiotensin-Converting Enzyme (ACE) inhibitors.

“This medication is applied across domains where additional symptomatic support is needed to help manage conditions associated with increased physiological stress.”

Quick Fact: Relief for Circulatory Strain
Supports the management of elevated blood pressure to ease chronic systemic burden and assists with maintaining functional stability in the post-event context.

Eligibility for Тарег (Valsartan): Official Regulatory Information

The eligibility for using Тарег (Valsartan) is determined by specific population characteristics and underlying medical conditions, as defined in regulatory documents.

---

Populations Contraindicated for Use

Тарег is strictly contraindicated and must not be used in the following groups:

• Patients with documented hypersensitivity to Valsartan or any component of the product.
• Pregnant women during the second and third trimesters. Use is also not recommended in the first trimester.
• Individuals with severe Hepatic Impairment, Biliary Cirrhosis, or Cholestasis.
• Patients with Type 2 Diabetes Mellitus or moderate-to-severe Renal Impairment when taking Aliskiren.

---

Age- and Condition-Based Restrictions

Population Group	Eligibility Status	Labeled Restriction
Pediatrics	Approved for hypertension only.	Not recommended for children under six years of age.
Lactating Women	Not recommended.	Risk to the nursing infant is not excluded.
Renal Function	Use requires caution.	Caution advised in patients with renal artery stenosis or severe renal impairment.

Use is not established for heart failure or post-myocardial infarction in pediatric patients. Caution is also advised in patients who are salt- or volume-depleted.

Interactions with other medicines and products

The interaction profile of Тарег is primarily governed by its relationship with drug transport and metabolism pathways, specifically the combined activity of P-glycoprotein (P-gp) and the cytochrome P450 3A (CYP3A) enzyme system.

Interacting Agents	Regulatory Constraint	Mechanistic Basis
Combined P-gp and Strong CYP3A Inhibitors	Avoid Concomitant Use	Increased exposure, documented to raise bleeding risk.
Combined P-gp and Strong CYP3A Inducers	Avoid Concomitant Use	Decreased exposure, documented to raise risk of thromboembolic events.
Other Anticoagulants and Antiplatelet Agents (e.g., NSAIDs, Aspirin)	Use requires clinical evaluation	Documented increase in bleeding risk.

Official regulatory documents mandate the complete avoidance of combined P-gp and strong CYP3A inhibitors, as this combination is documented to significantly increase the systemic exposure of Тарег and carries an elevated risk of bleeding. Similarly, the co-administration of combined P-gp and strong CYP3A inducers must also be avoided, as this is documented to decrease the drug's plasma concentration, which may reduce its efficacy against thromboembolic events. For other agents that affect blood clotting, such as other anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), or aspirin, the regulatory information indicates a heightened risk of bleeding. Therefore, the official product labeling requires that a careful clinical assessment be performed to ensure that the anticipated clinical benefit of these combinations outweighs the documented increase in bleeding risk.

Selective Blockade of the AT1 Receptor

Valsartan acts as a selective antagonist that competitively blocks the Angiotensin II type 1 ( AT1) receptor. This molecular action prevents the binding of Angiotensin II to its primary receptor, thereby suppressing the initiation of AT1-mediated signaling cascades that lead to cellular contraction and proliferation.

---

Modulation of Vascular Tone and Resistance

The molecular blockade interferes with the signaling processes within vascular smooth muscle cells that promote vessel contraction. By inhibiting this key step, Valsartan promotes vasodilation (vessel widening), leading to a reduction in Systemic Vascular Resistance (SVR). This physiological adjustment contributes to the net reduction in pressure within the circulatory system.

---

Inhibition of Aldosterone-Driven Volume Control

Beyond the blood vessels, the AT1 receptor blockade suppresses the signal for the release of Aldosterone from the adrenal glands. Reduced Aldosterone levels diminish the kidney's drive to retain sodium and water, promoting natriuresis and subsequently reducing the overall circulating plasma volume. This mechanism contributes a volume-regulating component to the molecule's resulting physiological changes.

Тарег (Valsartan) is administered exclusively via the oral route, available as film-coated tablets in four strengths (40 mg, 80 mg, 160 mg, and 320 mg) and a specialized oral suspension formulation. The medicine may be taken with or without food. It is explicitly stated that the tablets and the oral suspension are not substitutable on a milligram-for-milligram basis due to differences in systemic absorption, and the suspension requires specific compounding.

The official dosing schedule is determined by the condition being addressed. For hypertension, the typical starting dose is 80 mg or 160 mg administered once daily, with the maximum labeled dose set at 320 mg daily. For heart failure and post-myocardial infarction treatment, the drug is administered twice daily in divided doses, initiating at a lower amount, such as 40 mg twice daily for heart failure.

Protocols for these conditions mandate a structured titration schedule to gradually reach the target maintenance dose of 160 mg twice daily. Dose increases should be made at intervals of at least two weeks to assess tolerability, and the maximum antihypertensive effect is usually attained after four weeks of continuous use.

Specific usage constraints apply to certain populations. For patients with mild to moderate hepatic impairment without cholestasis, the total daily dose should not exceed 80 mg. Older adults typically do not require an initial dosage adjustment. If a dose is missed, the next scheduled dose should be taken at the usual time; a double dose should not be taken to make up for the omission.

Research evidence / Overview of studies for Тарег

Evidence Overview for High Blood Pressure (Hypertension)

Research examining Тарег (Valsartan) for patients with elevated blood pressure primarily relies on large-scale, long-term Randomized Controlled Trials (RCTs). These studies were designed to track how the medication was observed in studies when compared to a placebo or other treatment interventions over extended periods. Studies monitored several key outcomes, including the effect on systolic and diastolic blood pressure (BP) values, as well as the long-term patterns of major cardiovascular events such as heart attack and stroke.

Research Evidence for Chronic Heart Failure

The evidence base for Тарег in people with chronic heart failure has been evaluated through major, controlled clinical trials. These studies typically involved adding Valsartan to existing standard treatments and monitoring outcomes in relation to a placebo group over multiple years. Research examined outcomes related to survival, including all-cause death and cardiovascular death, as well as the rate of hospitalization due to heart failure.

What remains uncertain relates to its use in specific combination therapies. The evidence is limited to clearly support the use of Valsartan together with an ACE inhibitor and a beta-blocker.

Studies in Patients After a Heart Attack (Post-Myocardial Infarction)

Research exploring the use of Тарег after an acute heart attack focused on high-risk patients who had developed complications such as heart failure or demonstrated left ventricular dysfunction. These were comparative studies that either used Valsartan alone, an ACE inhibitor alone, or a combination of both agents.

Areas of Research Uncertainty and Study Gaps

While the evidence base for the major indications is extensive, some research areas have limited information for long-term outcomes beyond the duration of the main clinical trials. For chronic heart failure patients already on specific complex regimens, the evidence was associated with findings regarding the combination of Valsartan with both an ACE inhibitor and a beta-blocker. Furthermore, comparative evidence is lacking regarding head-to-head performance against all other antihypertensive classes for every specific cardiovascular outcome.

Key Studies & References

1. Valsartan: LiverTox - Clinical and Research Information on Drug-Induced Liver Injury

Common questions about Тарег (FAQ)

Q: Can children or teenagers use Тарег?

A: Official information indicates that this medicine is approved for use in pediatric patients with high blood pressure (hypertension) who are in the 6 to 16 years age range. However, the labeling does not recommend use in children under 6 years old, as noted in the official product information.

Q: Is Тарег safe for older adults (seniors)?

A: Studies noted in the official documentation found no overall difference in how effective or safe the drug was when comparing older and younger adults. Nonetheless, the documentation acknowledges that some older individuals may have a greater sensitivity to the medicine’s effects.

Q: Are there any specific medical conditions that disqualify a person from taking Тарег?

A: Yes, regulatory documents list specific contraindications. The medicine is contraindicated (should not be used) in pregnant women due to the serious risk of harm to the fetus. It is also contraindicated for patients with a known hypersensitivity (severe allergic reaction risk) to any of its components, and for use alongside aliskiren in patients who have diabetes.

Q: What is the main reason doctors prescribe Тарег?

A: According to official indications, this medicine is used to treat high blood pressure (hypertension), to manage heart failure, and to improve survival after a heart attack (post-myocardial infarction).

Q: Is Тарег considered a long-term or short-term medicine?

A: The drug is indicated for chronic (long-lasting) health issues such as heart failure and hypertension. Therefore, the official product information implies it is typically used as a tool for long-term management as part of comprehensive care for these conditions.

Q: What class of drug does Тарег belong to?

A: Тарег is officially classified as an Angiotensin II Receptor Blocker (ARB). It is a class of medicine associated with preventing the action of angiotensin II, a hormone that can narrow blood vessels.

Q: Is there a generic version of Тарег available?

A: Yes, official drug history records confirm that a generic formulation of the active ingredient, valsartan, has been approved and is available.

Q: Can Тарег cause weight gain or weight loss?

A: In some post-marketing reports, weight gain is noted as a less common side effect. Additionally, official sources indicate that unexplained weight change is a reported adverse event that may require medical review.

Q: Does Тарег affect sleep or cause drowsiness?

A: While the regulatory documents do not list 'drowsiness' directly, common side effects include dizziness and fatigue. These reported side effects may affect alertness or contribute to a feeling of being tired.

Q: Are headaches a common side effect of Тарег?

A: Yes, official reports from clinical trials indicate that headache is listed as one of the most frequently reported side effects when taking this medicine for high blood pressure.

Q: Is it normal to feel slightly nauseous when first starting Тарег?

A: Official post-marketing experience reports that nausea has been noted as an uncommon side effect.

Q: What are the most commonly reported side effects of Тарег?

A: According to the official adverse reaction data from clinical trials, the most commonly reported side effects include dizziness, hypotension (low blood pressure), diarrhea, fatigue, and headache.

Q: Can Тарег interact with common pain relievers like ibuprofen or aspirin?

A: Official documentation notes a potential interaction with NSAIDs (Nonsteroidal Anti-inflammatory Drugs) like ibuprofen. This combination may increase the risk of problems with kidney function and could also reduce the effectiveness of the drug in lowering blood pressure.

Q: Are there any foods or drinks I should avoid while taking Тарег?

A: Official product information notes caution regarding potassium-containing supplements or salt substitutes containing potassium. The medicine can increase potassium levels in the blood, and combining it with potassium-rich products may increase the risk of high blood potassium (hyperkalemia).

Q: Does drinking alcohol while on Тарег pose a risk?

A: The medicine can cause low blood pressure (hypotension) and dizziness. Because alcohol also has the effect of lowering blood pressure, consuming it while taking the drug may increase the risk of these effects occurring.

Q: What are the concerns about using Тарег during pregnancy or breastfeeding?

A: This drug carries an official Boxed Warning for Fetal Toxicity, meaning it can harm a developing fetus. The Boxed Warning indicates that discontinuation is necessary upon detection of pregnancy. For breastfeeding, official guidance indicates that breastfeeding is generally not recommended during use.

Q: Is Тарег okay for people who have kidney issues?

A: Official warnings state that the medicine can cause changes in how the kidneys function, including a risk of acute kidney failure. Patients with existing kidney issues, such as renal artery stenosis, are noted to be at particular risk, and kidney function should be reviewed regularly.

Q: What liver conditions might prevent someone from using Тарег?

A: Official documents state that patients with mild-to-moderate liver impairment require caution in dosage consideration. While severe impairment is not strictly forbidden, official safety reports note very rare instances of liver inflammation (hepatitis) in post-marketing experience.

Q: Has Тарег been approved by the FDA or other major health organizations?

A: Yes, the active ingredient was first approved by the U.S. Food and Drug Administration (FDA) in 1996, confirming its regulatory status.

Q: What do clinical trial summaries say about the effectiveness of Тарег?

A: Clinical evidence summarized in the official labeling indicates that the drug’s ability to lower blood pressure is associated with reducing the risk of fatal and nonfatal cardiovascular events, such as strokes and heart attacks.

Q: Is Тарег known to cause dependency or withdrawal symptoms?

A: Official classification states this medicine is not considered a controlled substance and is not known to lead to addiction or dependency. Discontinuation is typically discussed in the context of managing blood pressure or side effects.

Q: Is Тарег safe to use if I have high blood pressure?

A: The drug is officially indicated (approved) for the treatment of high blood pressure (hypertension). The purpose of its use is to help lower blood pressure.

Q: What is the risk of a severe allergic reaction to Тарег?

A: Official post-marketing reports have indicated rare instances of a severe hypersensitivity reaction called angioedema. This involves serious swelling of the face, lips, throat, and tongue.

Q: Is there any official guidance on driving or operating machinery while taking Тарег?

A: Official documentation notes that side effects such as dizziness or low blood pressure can occur. Patients are advised to consider the potential effects on their alertness and coordination before engaging in activities that require focus, such as driving or operating heavy machinery.

Q: How is Тарег typically packaged or available (e.g., tablet, capsule)?

A: The drug is officially available in two primary forms: as film-coated tablets and as a specialized oral suspension formulation.

Q: Is Тарег considered a controlled substance?

A: No, according to regulatory data and official drug classifications, this medicine is not classified as a controlled substance.

Q: Can Тарег affect birth control or fertility?

A: Official animal studies specifically examined the potential effects on fertility. These studies did not demonstrate adverse effects on the reproductive performance of male or female subjects.

Q: Is it true that Тарег is less effective in certain genetic populations?

A: Some official clinical considerations for this class of medicine note that certain antihypertensive drugs may be less effective at lowering blood pressure when used alone in Black patients compared to non-Black patients.

Q: What does the patient information leaflet say about stopping Тарег?

A: Official warnings state that dosage reduction or permanent discontinuation may be necessary in the event of excessive low blood pressure (hypotension) or dangerously high potassium levels (hyperkalemia). These are specific medical reasons for treatment cessation.

Q: Is the purpose of Тарег simply to manage symptoms or does it treat the cause?

A: The drug manages chronic conditions by lowering blood pressure and helping to reduce the overall risk of major long-term cardiovascular events. Its usage is aimed at reducing the progression and risks associated with these chronic diseases.

Q: How does Тарег relate to conditions affecting the heart?

A: The medicine is officially approved for heart-related conditions, specifically the treatment of heart failure and to improve the patient's prognosis following a heart attack (post-myocardial infarction).

Q: What are the signs of an overdose with Тарег, according to official sources?

A: Official information indicates that the most likely signs of an overdose are related to extreme low blood pressure (hypotension). These symptoms may include severe dizziness, fainting, and experiencing an unusually fast or slow heart rate.

Q: Is the oral suspension substitutable for the tablets on a milligram-for-milligram basis?

A: No, official prescribing information explicitly states that the tablets and the specialized oral suspension are not interchangeable on a milligram-for-milligram basis. This is due to differences in how the two formulations are absorbed by the body.

How to Store and Dispose of Тарег (Valsartan)

Official regulatory documents define specific storage and disposal requirements for Tagrisso (Valsartan) tablets and the prepared oral suspension.

Storage Conditions

Valsartan tablets must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be stored in its original container and kept tightly closed to protect it from moisture. The prepared oral suspension has a finite labeled stability, remaining stable for 30 days at room temperature (below 30 C) or 75 days if refrigerated (2 C to 8 C). All forms must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Valsartan must be disposed of according to local regulations. It is strictly required that the medication not be thrown away via wastewater or household waste to prevent environmental contamination.